Philip Seth Bernard
Physician in Salt Lake City, UT

License number
Utah 4885825-1205
Issued Date
Apr 3, 2001
Expiration Date
Jan 31, 2018
Category
Physician
Type
Physician & Surgeon
Address
Address
Salt Lake City, UT
Education
UNIVERSITY OF UTAH SCHOOL OF MEDICINE

Personal information

See more information about Philip Seth Bernard at radaris.com
Name
Address
Phone
Philip Bernard
1855 E Yale Ave, Salt Lake City, UT 84108

Professional information

Philip Bernard Photo 1

Molecular Diagnosis And Typing Of Lung Cancer Variants

US Patent:
2010023, Sep 16, 2010
Filed:
Jun 2, 2008
Appl. No.:
12/602649
Inventors:
David N. Hayes - Chapel Hill NC, US
Charles M. Perou - Carrboro NC, US
Philip Bernard - Salt Lake City UT, US
Assignee:
University of North Carolina at Chapel Hill - Chapel Hill NC
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and/or proteins that are selectively expressed at a high or low level in certain tumor subtypes. Biomarker expression can be assessed at the protein or nucleic acid level.


Philip Bernard Photo 2

Gene Expression Profiles To Predict Breast Cancer Outcomes

US Patent:
2011014, Jun 16, 2011
Filed:
Jun 1, 2009
Appl. No.:
12/995450
Inventors:
Charles M. Perou - Carrboro NC, US
Joel S. Parker - Apex NC, US
James Stephen Marron - Durham NC, US
Andrew Nobel - Chapel Hill NC, US
Philip S. Bernard - Salt Lake City UT, US
Matthew Ellis - St.Louis MO, US
Elaine Mardis - Troy IL, US
Torsten O. Nielsen - North Vancouver, CA
Maggie Cheang - Vancouver, CA
International Classification:
G06F 15/18, C12Q 1/68
US Classification:
706 12, 435 61
Abstract:
Methods for classifying and for evaluating the prognosis of a subject having breast cancer are provided. The methods include prediction of breast cancer subtype using a supervised algorithm trained to stratify subjects on the basis of breast cancer intrinsic subtype. The prediction model is based on the gene expression profile of the intrinsic genes listed in Table 1. This prediction model can be used to accurately predict the intrinsic subtype of a subject diagnosed with or suspected of having breast cancer. Further provided are compositions and methods for predicting outcome or response to therapy of a subject diagnosed with or suspected of having breast cancer. These methods are useful for guiding or determining treatment options for a subject afflicted with breast cancer. Methods of the invention further include means for evaluating gene expression profiles, including microarrays and quantitative polymerase chain reaction assays, as well as kits comprising reagents for practicing the methods of the invention.


Philip Bernard Photo 3

Associate Professor At University Of Utah

Position:
Associate Professor at University of Utah
Location:
Greater Salt Lake City Area
Industry:
Higher Education
Work:
University of Utah - Associate Professor


Philip Bernard Photo 4

Methods Of Treating Breast Cancer With Anthracycline Therapy

US Patent:
2013000, Jan 3, 2013
Filed:
Mar 15, 2012
Appl. No.:
13/421367
Inventors:
Charles M. Perou - Carrboro NC, US
Matthew J. Ellis - St. Louis MO, US
Philip S. Bernard - Salt Lake City UT, US
Torsten O. Nielsen - North Vancouver, CA
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
British Columbia Cancer Agency Branch - Vancouver
University of Utah Research Foundation - Salt Lake City UT
Washington University - St. Louis MO
International Classification:
A61K 31/704, A61K 31/675, A61K 31/513, A61K 31/519, A61K 39/395, A61K 33/24, A61K 31/7068, A61K 31/565, A61K 38/02, A61P 35/00, G01N 33/574, C12Q 1/68, G01N 21/64, C40B 30/04, C40B 40/06, A61K 31/136
US Classification:
4241331, 514 27, 514656, 514110, 514274, 514249, 514 83, 4241421, 424649, 514 49, 514171, 514 11, 435 723, 435 611, 506 9, 506 16
Abstract:
The application describes methods for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including an anthracycline. The application also describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including anthracycline and administering the therapy in subjects when it is found that anthracycline is likely to be effective.


Philip Bernard Photo 5

Methods Of Treating Breast Cancer With Taxane Therapy

US Patent:
2013034, Dec 26, 2013
Filed:
Nov 30, 2012
Appl. No.:
13/690891
Inventors:
Charles M. Perou - Carrboro NC, US
Philip S. Bernard - Salt Lake City UT, US
Torsten O. Nielsen - North Vancouver, British Columbia, CA
Matthew J. Ellis - St. Louis MO, US
Joel S. Parker - Chapel Hill NC, US
Miguel Martin - Madrid, ES
Eva Carrasco - Madrid, ES
Rosalia Caballero - Madrid, ES
International Classification:
C12Q 1/68
US Classification:
514 34, 514449, 435 612, 514274, 514 90
Abstract:
The application describes methods for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including a taxane or a taxane derivative. The application also describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including a taxane or a taxane derivative and administering the therapy in subjects when it is found that a taxane or a taxane derivative is likely to be effective.


Philip Bernard Photo 6

Simultaneous Screening And Identification Of Sequence Alterations From Amplified Target

US Patent:
6753141, Jun 22, 2004
Filed:
Jan 25, 2001
Appl. No.:
09/770770
Inventors:
Philip S. Bernard - Salt Lake City UT
Carl T. Wittwer - Salt Lake City UT
Gregory Pritham - Easton NH
Assignee:
The University of Utah - Salt Lake City UT
International Classification:
C12Q 168
US Classification:
435 6, 435 911, 435 912, 935 77, 935 78
Abstract:
Methods for identifying and locating alterations in a nucleic acid having a known sequence are provided. The methods involve measuring the melting temperature of probe nucleic acids hybridized to a target nucleic acid. The methods take advantage of the differential dissociation temperatures of a probe from a target resulting from mismatches at different locations along the region of the target to which the probe hybridizes.


Philip S Bernard Photo 7

Philip S Bernard, Salt Lake City UT

Specialties:
Clinical Pathology
Address:
1375 Bryan Ave, Salt Lake City 84105
(801) 467-7927 (Phone)
Languages:
English


Philip Bernard Photo 8

Multiplex Genotyping Using Fluorescent Hybridization Probes

US Patent:
6140054, Oct 31, 2000
Filed:
Sep 30, 1998
Appl. No.:
9/164023
Inventors:
Carl T. Wittwer - Salt Lake City UT
Philip S. Bernard - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
The present invention is directed to a mutation detection kit and method of analyzing multiple loci of one or more nucleic acid sequences for the presence of mutations or polymorphisms. More particularly, the present invention relates to the use of the polymerase chain reaction (PCR) and fluorescently labeled oligonucleotide hybridization probes to identify mutations and polymorphisms based on melting curve analysis of the hybridization probes.


Philip Bernard Photo 9

Methods And Compositions Involving Intrinsic Genes

US Patent:
2009029, Dec 3, 2009
Filed:
Nov 17, 2006
Appl. No.:
12/094898
Inventors:
Matthew J. Ellis - St Louis MO, US
Philip S. Bernard - Salt Lake City UT, US
Robert A. Palais - Salt Lake City UT, US
Charles M. Perou - Carrboto NC, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
The University of North Carolina at Chapel Hill - Chapel Hill NC
Washington University - St. Louis MO
International Classification:
C12Q 1/68, G06F 19/00
US Classification:
702 19, 435 6
Abstract:
Disclosed are compositions and methods related intrinsic gene sets and methods and compositions related to detecting and classifying cancer.


Philip Bernard Photo 10

Solution-Based Color Compensation Adjusted For Temperature And Electronic Gains

US Patent:
6197520, Mar 6, 2001
Filed:
Aug 13, 1999
Appl. No.:
9/374422
Inventors:
Carl T. Wittwer - Salt Lake City UT
Gregory Pritham - Salt Lake City UT
Philip Bernard - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12Q 168, C12P 1934
US Classification:
435 6
Abstract:
The present invention is directed to a method of analyzing at least two analytes at the same time using at least two fluorescent detecting entities. More particularly, the present invention relates to the use of fluorescently labeled hybridization probes to identify the genotypes of a nucleic acid sample at more than one locus by measuring fluorescence throughout a range of temperatures and correcting for temperature-dependent spectral overlap of the fluorescent probes.